TIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 Trial
BOTHELL, Wash., & COPENHAGEN, Denmark--(BUSINESS WIRE)--Oct 22, 2023--